SPX-106T

**SPX-106T** was an investigational oral fixed-dose combination developed by Spherix for hypertriglyceridemia, dyslipidemia, atherosclerosis, metabolic syndrome, and related cardiovascular-risk conditions. It combines **SPX-106**, an undisclosed small-molecule lipid-lowering candidate, with **d-tagatose**, a rare sugar. In preclinical models, Spherix reported reductions in triglycerides, VLDL and LDL cholesterol, atherosclerotic plaque burden, fat deposition, and body-weight gain. The proposed complementary mechanism was inhibition of intestinal fructose absorption by d-tagatose together with promotion of lipid catabolism by SPX-106; the precise molecular target of SPX-106 was not publicly disclosed. ([prnewswire.com](https://www.prnewswire.com/news-releases/spherix-drug-candidate-spx-106-shows-statistically-significant-reductions-in-serum-triglycerides-in-preclinical-testing-123043698.html))

Other names

d-tagatose + SPX-106SPX-106 + d-tagatoseSPX106TSPX-106TSPX 106T